Developing a selection framework for digital measures of Parkinson’s disease progression for the EJS ACT-PD trial
Objective: To develop a selection process for digital measures (DMs) to include as exploratory outcome measures of Parkinson’s disease (PD) progression in a platform disease…A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data
Objective: To evaluate the effect on slowing motor progression and the safety of prasinezumab, a humanized monoclonal antibody targeting aggregated alpha-synuclein, in individuals with early…Mortality Rate, Cause of Death and Factors Associated with Mortality in Late Stage Parkinson’s Disease
Objective: The aim was to carry out a long-term follow-up of a cohort of patients in late stage Parkinson’s disease (PD) with focus on mortality…Formulations and Assessments of Intra-nasal noses to brain curcumin delivery using reversible nanoparticles for Parkinsonism treatment: A Preclinical Approach
Objective: Parkinson's disease (PD) is a prevalent neurological illness that is typified by bradykinesia, postural instability, tremor, and stiffness. An increasing body of research suggests…Oropharyngeal Adverse Events in Parkinson’s Patients with Motor Fluctuations Treated with Apomorphine Sublingual Film
Objective: This post-hoc analysis of Study CTH-301 assessed the occurrence of oropharyngeal treatment-emergent adverse events (TEAEs) in patients with Parkinson’s disease included in this study.…Pharmacokinetics of Levodopa after Subcutaneous bolus delivery of foslevodopa/foscarbidopa
Objective: To characterize the pharmacokinetics (PK) of levodopa (LD) after bolus delivery of foslevodopa/foscarbidopa Background: Foslevodopa/foscarbidopa is a soluble formulation of LD/CD prodrugs delivered as…Longitudinal Changes in Quality of Life After Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
Objective: To clarify longitudinal changes in QOL in PD after STN-DBS. Background: While it is well known that motor complications are dramatically improved after subthalamic…Antipsychotic Prescriptions Among Nursing Home Residents with Parkinson’s Disease in the End-of-Life Period
Objective: To determine whether antipsychotic prescriptions differ between community-dwelling and nursing home residents with PD in the last 6 months of life. Background: Most antipsychotics…Metabolic Regulators of Mitochondrial DNA Release in Cellular Models of PRKN-linked Parkinson’s Disease
Objective: Explore metabolic modulation as a disease-modifying target for inflammation in PRKN-PD Background: The release of mitochondrial DNA (mtDNA) is a well-documented phenotype in PRKN-linked…Single cell transcriptomics of peripheral blood mononuclear cells and associations with clinical outcomes in Parkinson’s disease
Objective: To assess transcriptomics signatures for monocytes and T-cells in different stages of Parkinson’s disease (PD) compared to controls and possible correlations with clinical outcomes.…
- « Previous Page
- 1
- …
- 178
- 179
- 180
- 181
- 182
- …
- 436
- Next Page »